Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, Wells Fargo analyst Derek Archila reiterated a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) and set a price target of $123.00. Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported that it used $12.6 million of cash in its operating activities during the three months ended June 30, 2025. Management reported that the ...

Interim Results for the period ended 30 June 2025 LONDON, UK / ACCESS Newswire / September 30, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose Shares are admitted to the equity shares (transition) category of the Official List, announces its unaudited interim results for the six-month period ended 30 June 2025. All financial amounts are stated in GBP British pounds unless otherwise indicated. ...

Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to advancing innovative tre ...

Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to advancing innovative tre ...

PresentationI will now hand the conference over to your speaker host, Dan Faga, President and CEO of Anaptys. Please go ahead, sir.Good day. Thank you for standing by. Welcome to the Anaptys conference call. [Operator Instructions] Please note that today's conference may be recorded.Daniel FagaPresident, CEO & Director Good afternoon and thank you for joining us today. We are excited to discuss today the further evolution of Anaptys with our intention to separate our biopharma operations from our substantia ...

公司评级与市场表现 - Jefferies于2025年9月29日将MoonLake Immunotherapeutics评级从"买入"下调至"持有" 反映保守观点 [2] - 评级下调时股价为6 14美元 较历史高点大幅下跌 [2] - 股价当前报6 25美元 日内波动区间5 96-7 13美元 年内峰值62 75美元 最低点5 95美元 [5] 临床试验进展 - 第3阶段VELA-1和VELA-2试验第16周结果触发市场负面反应 [3] - 试验采用HiSCR75终点指标 评估sonelokimab对脓肿和炎症结节数量减少75%的效果 [3] - 试验设计包含838名患者 120mg剂量组与安慰剂对照 第16周后所有患者接受120mg剂量直至第48周 最终评估在第52周 [4] 股价与市值变动 - 股价累计下跌约89 93% 相当于55 75美元跌幅 [4] - 公司当前市值约3 9657亿美元 日交易量达7672万股 [5] 行业竞争定位 - MoonLake专注于炎症性疾病创新疗法开发 主要产品sonelokimab针对特定炎症适应症 [1] - 公司在免疫治疗领域与多家生物技术企业存在激烈竞争 [1]

Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associ ...

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is among the hidden penny stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) by a whopping 482.3%. Following the purchase of 239,751 shares, the global investment bank now owns 289,461 shares of the company’s stock, valued at approximately $741,000. Investing in Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) is like planting a tree; with time and patience, it o ...

公司股价表现 - MoonLake Immunotherapeutics股价跌至624美元 跌幅达8993% [1][6] - KALA BIO股价跌至213美元 跌幅达8882% [2][6] - IO Biotech股价跌至035美元 跌幅达7731% [3][6] - Maris-Tech股价跌至022美元 跌幅达7116% [4] 公司特定事件 - MoonLake Immunotherapeutics面临律师事务所潜在索赔调查 [1] - KALA BIO停止特定眼病实验性治疗药物开发 [2] - IO Biotech遭FDA建议不基于IOB-013临床试验数据提交生物制剂许可申请 将进行重组并裁员约50% [3] - Maris-Tech作为数字音视频硬件软件解决方案提供商 可能受行业技术升级或竞争压力影响 [4] 行业特征 - 生物制药与技术行业公司出现显著股价波动 [5] - 市场情绪、行业趋势及公司特定发展是影响股价的关键因素 [5]

AnaptysBio (NasdaqGS:ANAB) Update / Briefing September 29, 2025 04:30 PM ET Company ParticipantsDaniel Faga - President, CEO & DirectorAnupam Rama - Executive Director - Biotechnology Equity ResearchAlex Thompson - Managing DirectorDennis Mulroy - CFOConference Call ParticipantsYatin Suneja - Senior MD & Equity Research Analyst - BiotechnologyJoseph Thome - MD & Senior Biotechnology Equity Research AnalystAndy Chen - Director & Senior Equity Research AnalystYasmeen Rahimi - MD & Senior Research AnalystDavid ...